BIOMAT Database Logo BIOMAT Database Logo

Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). 2002

Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Omiya Research Laboratory, Nikken Chemicals Co., Ltd., 1-346, Kitabukuro-cho, Saitama-shi, 330-0835, Saitama, Japan. souyaku@jade.dti.ne.jp

Compounds 1 or 2 which possess dual-acting PAF antagonist/TxSI in a previous paper were modified and evaluated for the dual-acting activity. It was found that several compounds were potent dual-acting PAF antagonist/TxSI in and ex vivo. 6-(2-Chlorophenyl)-3-[4-[(E/Z)-6-ethoxycarbonyl-1-(3-pyridyl)-1-hexenyl]phenylmethyl]-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido[4',3': 4,5]thieno[3,2-f]triazolo[4,3-a]diazepine (12) is excellent orally dual-acting PAF antagonist/TxSI.

UI MeSH Term Description Entries
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D010980 Platelet Membrane Glycoproteins Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors. PM-GP,Platelet Glycoprotein,Platelet Membrane Glycoprotein,PM-GPs,Platelet Glycoproteins,Glycoprotein, Platelet,Glycoprotein, Platelet Membrane,Glycoproteins, Platelet,Glycoproteins, Platelet Membrane,Membrane Glycoprotein, Platelet,Membrane Glycoproteins, Platelet,PM GP
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013876 Thiophenes A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur. Thiophene
D013930 Thromboxane-A Synthase An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2

Related Publications

Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
[Research progress of platelet activating factor(PAF) receptor antagonist].
April 2018, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Biological activity of platelet activating factor-amidophosphonate (PAF-AP), a novel phosphonolipid selective inhibitor of platelet activating factor (PAF).
December 1985, Biochemical and biophysical research communications,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants.
January 2005, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
[Thromboxane A2 synthase inhibitor and receptor antagonist].
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.
March 1985, Biochemical and biophysical research communications,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
[Platelet-activating factor (PAF) receptor-related pathophysiology].
June 1999, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): effect of kadsurenone, a PAF-receptor antagonist.
January 1986, International journal of tissue reactions,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist.
March 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice.
January 2000, Progress in lipid research,
Masakazu Fujita, and Taketsugu Seki, and Haruaki Inada, and Kazuhiro Shimizu, and Akane Takahama, and Tetsuro Sano
CV-3988 - a specific antagonist of platelet activating factor (PAF).
April 1983, Life sciences,
Copied contents to your clipboard!